ARS Pharmaceuticals (SPRY) Enterprise Value (2021 - 2025)
Historic Enterprise Value for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to -$288.2 million.
- ARS Pharmaceuticals' Enterprise Value fell 4084.81% to -$288.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$288.2 million, marking a year-over-year decrease of 4084.81%. This contributed to the annual value of -$314.0 million for FY2024, which is 3751.18% down from last year.
- Latest data reveals that ARS Pharmaceuticals reported Enterprise Value of -$288.2 million as of Q3 2025, which was down 4084.81% from -$240.1 million recorded in Q2 2025.
- ARS Pharmaceuticals' 5-year Enterprise Value high stood at -$60.1 million for Q4 2021, and its period low was -$374.2 million during Q1 2021.
- Its 5-year average for Enterprise Value is -$257.9 million, with a median of -$258.0 million in 2022.
- Over the last 5 years, ARS Pharmaceuticals' Enterprise Value had its largest YoY gain of 3216.37% in 2022, and its largest YoY loss of 35682.2% in 2022.
- Quarter analysis of 5 years shows ARS Pharmaceuticals' Enterprise Value stood at -$60.1 million in 2021, then plummeted by 356.82% to -$274.4 million in 2022, then rose by 16.77% to -$228.4 million in 2023, then tumbled by 37.51% to -$314.0 million in 2024, then rose by 8.22% to -$288.2 million in 2025.
- Its Enterprise Value stands at -$288.2 million for Q3 2025, versus -$240.1 million for Q2 2025 and -$275.7 million for Q1 2025.